|
市場調查報告書
泛焦慮症市場
Are There Changes Ahead for the Generalized Anxiety Disorder Market?
|
泛焦慮症市場 是由出版商Decision Resources, Inc.在2009年01月所出版的。
這份英文市場調查報告書包含21 Pages 價格從美金2300起跳。
泛焦慮症市場有許多非專利藥品製造商進入，創造競爭激烈的新藥上市環境。
本報告書內容包括：泛焦慮症概要及流行病學、現在的治療方法、新興治療方法、與2007年表現的比較及未來預測等。內容綱要摘記如下：
實施概要
介紹
泛焦慮症概要
泛焦慮症的罹患率
現在的治療方法
- 血清素再度攝取抑制劑
- 血清素及正腎上腺素再度攝取抑制劑
- 苯環類藥物
新興治療方法
- Sanofi-Aventis的Saredutant
- 武田藥品工業／Lundbeck的Lu AA21004
- Pfizer的Lyrica及PD-332334
- Synosia Therapeutics的Rufinamide
- Sepracor的SEP-225441
2007年的表現及未來預測
圖表
Abstract
Introduction
Generalized anxiety disorder (GAD) is a prevalent psychiatric disorder in the
major pharmaceutical markets, and drug therapy is considered the most
effective treatment. The therapy market for GAD is crowded and includes many
generic players, creating a diffi cult environment for launching new agents.
Nonetheless, several emerging agents are set to challenge current market
leaders.
Get the Answers You Need to Shape Your Strategy
- GAD can be very debilitating, causing those affected to signifi cantly
limit their activities. How many people in the major pharmaceutical markets
we cover (United States, France, Germany, Italy, Spain, United Kingdom, and
Japan) have GAD? What brain structures and neurotransmitters have been
implicated in its development? How is the disease diagnosed?
- A variety of drug classes are used to treat GAD. What are the most
popular therapies for GAD? What are their benefi ts and drawbacks?
- Several new agents for GAD should launch in the next few years. What
agents are in the pipeline for GAD, and are they likely to replace any
existing agents? What changes can be expected in the GAD market over the next
fi ve years?
Scope
- Overview of GAD: disease description, diagnosis, and
pathophysiology.
- Epidemiology: total prevalent cases, diagnosed and drug-treated
populations.
- Current therapies: selective serotonin reuptake inhibitors,
serotonin and norepinephrine reuptake inhibitors, and benzodiazepines.
- Emerging therapies: Sanofi -Aventis' s Saredutant, Pfi zer' s Lyrica,
Pfi zer' s PD-332334, Takeda/Lundbeck' s Lu AA21004, Synosia Therapeutics' Rufi
namide, Sepracor' s SEP- 225441 and AstraZeneca' s AZD-7325.
- GAD market: 2007 statistics, outlook for emerging agents.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Overview of Generalized Anxiety Disorder
- Disease Defi nition
- Diagnosis
- Pathophysiology of Generalized Anxiety Disorder
- Serotonin
- Norepinephrine
- Gamma-Aminobutyric Acid
- Glutamate
- Corticotropin-Releasing Factor
- Substance P
- Prevalence of Generalized Anxiety Disorder
- Current Therapies for Generalized Anxiety Disorder
- Selective Serotonin Reuptake Inhibitors
- Serotonin and Norepinephrine Reuptake Inhibitors
- Benzodiazepines
- Emerging Therapies for Generalized Anxiety Disorder
- Sanofi -Aventis' s Saredutant
- Takeda/Lundbeck' s Lu AA21004
- Pfi zer' s Lyrica and PD-332334
- Synosia Therapeutics' Rufi namide
- Sepracor' s SEP-225441
- Generalized Anxiety Disorder Market: 2007 Statistics and Future Outlook
Tables
- 1. Common Symptoms of Generalized Anxiety Disorder
- 2. Common Risk Factors for Generalized Anxiety Disorder
- 3. Therapies Commonly Used to Treat Generalized Anxiety Disorder
- 4. Agents in Development to Treat Generalized Anxiety Disorder
- 5. Sales of Agents to Treat Generalized Anxiety Disorder, 2007
Figures
- 1. Structures of the Brain Implicated in Anxiety Disorders
- 2. Prevalent Cases of Generalized Anxiety Disorder in the Major
Pharmaceutical Markets, 2007 and 2012
|
